Oral quinolones versus intravenous β-lactam for the treatment of acute focal bacterial nephritis: a retrospective cohort study
European Journal of Clinical Microbiology & Infectious Diseases · 2024
DOI: 10.1007/s10096-024-04871-2 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2024. Verfasst von L Aceituno und 8 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Internal Medicine Department, Vall d'Hebron University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, beta-Lactams, Administration, Intravenous, Quinolones. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitat Autònoma de Barcelona.
Abstract (Originalsprache)
Background
Evidence regarding the best antibiotic regimen and the route of administration to treat acute focal bacterial nephritis (AFBN) is scarce. The aim of the present study was to compare the effectiveness of intravenous (IV) β-lactam antibiotics versus oral quinolones.
Methods
This is a retrospective single centre study of patients diagnosed with AFBN between January 2017 and December 2018 in Hospital Universitari Vall d’Hebron, Barcelona (Spain). Patients were identified from the diagnostic codifications database. Patients treated with oral quinolones were compared with those treated with IV β-lactam antibiotics. Therapeutic failure was defined as death, relapse, or evolution to abscess within the first 30 days.
Results
A total of 264 patients fulfilled the inclusion criteria. Of those, 103 patients (39%) received oral ciprofloxacin, and 70 (26.5%) IV β-lactam. The most common isolated microorganism was Escherichia coli (149, 73.8%) followed by Klebsiella pneumoniae (26, 12.9%). Mean duration of treatment was 21.3 days (SD 7.9). There were no statistical differences regarding therapeutic failure between oral quinolones and IV β-lactam treatment (6.6% vs. 8.7%, p = 0.6). Out of the 66 patients treated with intravenous antibiotics, 4 (6.1%) experienced an episode of phlebitis and 1 patient (1.5%) an episode of catheter-related bacteraemia.
Conclusions
When susceptible, treatment of AFBN with oral quinolones is as effective as IV β-lactam treatment with fewer adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Unit, Internal Medicine Department, Vall d'Hebron University Hospital, Barcelona, Spain.
- Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Internal Medicine Department, Mútua Terrassa University Hospital, Terrassa, Barcelona, Spain.
- Microbiology Department, Vic Hospital, Vic, Spain.
- Microbiology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
- Radiology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Förderung
- Universitat Autònoma de Barcelona
Zitieren
APA
Aceituno, L., Nuñez-Conde, A., Serra-Pladevall, J., Viñado, B., Castella, E., Escolà-Vergé, L., Pigrau, C., Falcó, V., & Len, Y. O. (2024). Oral quinolones versus intravenous β-lactam for the treatment of acute focal bacterial nephritis: a retrospective cohort study. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-024-04871-2
Vancouver
Aceituno L, Nuñez-Conde A, Serra-Pladevall J, Viñado B, Castella E, Escolà-Vergé L, et al. Oral quinolones versus intravenous β-lactam for the treatment of acute focal bacterial nephritis: a retrospective cohort study. European Journal of Clinical Microbiology & Infectious Diseases. 2024. doi:10.1007/s10096-024-04871-2
BibTeX
@article{Aceituno2024,
author = {Aceituno, L and Nuñez-Conde, A and Serra-Pladevall, J and Viñado, B and Castella, E and Escolà-Vergé, Laura and Pigrau, C and Falcó, V and Len, Y O},
title = {Oral quinolones versus intravenous β-lactam for the treatment of acute focal bacterial nephritis: a retrospective cohort study},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2024},
doi = {10.1007/s10096-024-04871-2}
}
EUVIMED